Lack of bioequivalence of gatifloxacin when coadministered with calcium-fortified orange juice in healthy volunteers

Journal of Clinical Pharmacology

Volumn 43, Issue 1, 2003, Pages 92-96

  Wallace, Allison W ^a   Victory, Jennifer M ^a   Amsden, Guy W ^a  

^a BASSETT RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GATIFLOXACIN;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CHELATION; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG ADSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; FEMALE; FLATULENCE; FOOD DRUG INTERACTION; GEOMETRY; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; ORANGE JUICE; TASTE DISORDER;

ADOLESCENT; ADULT; ANTI-INFECTIVE AGENTS; BEVERAGES; CALCIUM; CITRUS SINENSIS; FEMALE; FLUOROQUINOLONES; FOOD, FORTIFIED; FOOD-DRUG INTERACTIONS; HUMANS; MALE; THERAPEUTIC EQUIVALENCY;

EID: 0037215299     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270002239711     Document Type: Article

References (15)

1. Food and drug Administration: Food-Effect Bioavailability and Fed Bioequivalence Studies: Study Design, Data Analysis, and Labeling. Draft Guidance for Industry. Bethesda, MD: U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, 2001.
2. Nix DE, Watson WA, Lener M, Frost RW, Krol G, Goldstein H, et al: Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin. Clin Pharmacol Ther 1989;46:700-705.
3. Kara M, Hasinoff BB, McKay DW, Campbell NRC: Clinical and chemical interactions between iron preparations and ciprofloxacin. Br J Clin Pharmacol 1991;31:257-261.
4. Wallace AW, Amsden GW: Is it really OK to take this with food? Old interactions with a new twist. J Clin Pharmacol 2002;42:437-443.
5. Neuhofel AL, Wilton JH, Victory JM, Hejmanowski LG, Amsden GW: Lack of bioequivalence of ciprofloxacin when administered with calcium-fortified orange juice: A new twist on an old interaction. J Clin Pharmacol 2002;42:461-466,
6. Preston SL, Drusano GL, Berman AL, Fowler CL, Chow AT, Dornseif B, et al: Pharmacodynamics of levofloxacin: A new paradigm for early clinical trials. JAMA 1998;279:125-129.
7. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ: Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antirnicrob Agents Chemother 1993;37:1073-1081.
8. Tequin™ Product Information, Bristol-Myers Squibb, April 2000.
9. Dresser GK, Bailey DG, Leake BF, Schwarz UI, Dawson PA, Freeman DJ, et al: Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther 2002;71:11-20.
10. Takanaga H, Ohnishi A, Yamada S, Matsuo H, Morimoto S, Shoyama Y, et al: Polymetholxylated flavones in orange juice are inhibitors of P-glycoprotein but not cytochrome P450 3A4. J Pharmacol Exper Ther 2000;293:230-236.
11. Yamaguchi H, Yano I, Saito H, Inui K-I: Pharmacokinetic role of Pglycoprotein in oral bioavailability and intestinal secretion of grepafloxacin in vivo. J Pharmacol Exper Ther 2002;300:1063-1069.
12. 1. J Pharmacol Exper Ther 1997;282:955-960.
13. Yamaguchi H, Yano I, Hashimoto Y, Inui K-I: Secretory mechanisms of grepafloxacin and levofloxacin in the human intestinal cell line Caco-2. J Pharmacol Exper Ther 2000;295:360-366.
14. Cormet-Boyaka E, Huneau J-F, Mordrelle A, Boyaka PN, Carbon C, Rubinstein E, et al: Secretion of sparfloxacin from the human intestinal Caco-2 cell line is altered by P-glycoprotein inhibitors. Antimicrob Agents Chemother 1998;42:2607-2611.
15. Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, et al: Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium. Antimicrob Agents Chemother 1999;43:1067-1071.